Drag this link onto your Home button to make gastrotraining your Home Page.

Agent Promising for Refractory Colon Cancer (CME/CE)

(MedPage Today) — The novel nucleoside drug TAS-102 may boost survival in refractory metastatic colorectal cancer, a phase II trial showed.

Post a Comment

Comments are closed.